Amgen's CEO says he's 'confident' their $28B deal with Horizon can close despite FTC lawsuit
A day after federal antitrust authorities sued to stop Amgen’s $28 billion takeover of Horizon Therapeutics, Amgen’s CEO said he still expects the deal to close.
“We remain excited about the prospect of this combination,” Amgen CEO Robert Bradway said at an event hosted by the Financial Times on Wednesday in New York. (The FT owns a majority stake in Endpoints News, though the news organizations are independent.)
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.